IP Library Granted Patent US 7,825,229
Granted Patent B2
US 7,825,229 · App. 11/418,870 · Granted Nov 2, 2010

Lung cancer-related nucleic acids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,825,229
App. No.
11/418,870
Granted
Nov 2, 2010
Kind
B2
Abstract

Described are polynucleotides associated with lung cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of lung cancer. Also described are methods that can be used to identify modulators of the disease-associated polynucleotides. Also described are methods and compositions for linear amplification and labeling of a targeted nucleic acid. The amplified targeted molecules may be used in hybridization techniques like Luminex and Microarray analysis.

Claims (12)

1. An isolated nucleic acid of 21-24 nucleotides in length comprising a sequence selected from the group consisting of

(a) SEQ ID NO: 8662;

(b) the complement of (a); and

(c) a DNA encoding (a) or (b).

2. A vector comprising a heterologous sequence, wherein the heterologous sequence consists of the sequence of the nucleic acid of claim 1 .

3. A probe comprising a heterologous sequence, wherein the heterologous sequence consists of the sequence of the nucleic acid of claim 1 .

4. An isolated nucleic acid of 21-24 nucleotides in length comprising a sequence at least 90% identical to a sequence selected from the group consisting of:

(a) SEQ ID NO: 8662;

(b) the complement of (a); and

(c) a DNA encoding (a) or (b).

5. A vector comprising a heterologous sequence, wherein the heterologous sequence consists of the sequence of the nucleic acid of claim 4 .

6. A probe comprising a heterologous sequence, wherein the heterologous sequence consists of the sequence of the nucleic acid of claim 4 .

Assignments (2)
SECURITY INTEREST Recorded Dec 15, 2017
From: ROSETTA GENOMICS INC.; ROSETTA GENOMICS LTD; MINUET DIAGNOSTICS, INC.; CYNOGEN INC.
To: GENOPTIX, INC.
Reel/Frame 044899/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2006
From: BENTWICH, ITZHAK; AVNIEL, AMIR; KAROV, YAEL; AHARONOV, RANIT
To: ROSETTA GENOMICS LTD.
Reel/Frame 017641/0207 →